Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2026-02-15
Target enrollment:
Participant gender:
Summary
This preliminary clinical study evaluates the safety and initial efficacy of a novel therapy called Plasma-Activated Saline Solution (PASS) for bladder cancer patients. The study involves a one-week course of PASS administered via bladder infusion in five pre-surgical patients, using imaging and pathology analyses to assess tumor shrinkage and cancer cell death, while closely monitoring for any adverse reactions to explore the therapy's future potential.